Merck Climbs on the Emerging Markets Bandwagon

Merck wants to be either number one or two in China’s healthcare market within the next five to seven years. Much like all the major multinational pharmas, Merck is de-emphasizing its old business model, based on patented blockbuster drugs for Western markets, and turning to emerging markets for its future growth. The company wants emerging markets to generate one-fourth of all revenue by 2013, up from 18% currently. More details.... Stock Symbol: (NYSE: MRK)